ADAM10 and acute lymphoblastic leukemia: For example, T-cell acute lymphoblastic leukemia (T-ALL) is an aggressive blood cancer that is in urgent need of more effective treatments, and approximately two thirds of T-ALL is driven by activating mutations in Notch1 that allow its activation by ADAM10 without the need for normal ligand binding.